Cargando…
Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data
BACKGROUND: Vitamin-K antagonists (VKAs) present an effective anticoagulant treatment in deep venous thrombosis (DVT). However, the use of VKAs is limited because of the risk of bleeding and the necessity of frequent and long-term laboratory monitoring. Therefore, new oral anticoagulant drugs (NOACs...
Autores principales: | van Leent, Merlijn W. J., Stevanović, Jelena, Jansman, Frank G., Beinema, Maarten J., Brouwers, Jacobus R. B. J., Postma, Maarten J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524689/ https://www.ncbi.nlm.nih.gov/pubmed/26241880 http://dx.doi.org/10.1371/journal.pone.0135054 |
Ejemplares similares
-
Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands
por: Stevanović, J., et al.
Publicado: (2016) -
Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands: Clinical and Economic Effects
por: de Jong, Lisa A., et al.
Publicado: (2018) -
Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
por: Stevanović, Jelena, et al.
Publicado: (2014) -
Budget and health impact of switching eligible patients with atrial fibrillation to lower- dose dabigatran
por: Fens, Tanja, et al.
Publicado: (2023) -
Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate
por: van Gorp, Rick H., et al.
Publicado: (2021)